VEGF serum levels in depressed patients during SSRI antidepressant treatment

Ventriglia, Mariacarla; Zanardini, Roberta; Pedrini, Laura; Placentino, Anna; Nielsen, Maria Gabriela; Gennarelli, Massimo; Bocchio-Chiavetto, Luisella

doi:10.1016/j.pnpbp.2008.11.009

Cited by 64 publications

(64 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, patients were taking psychotrophic agents in the last two studies. In parallel with our findings Dome and colleagues and Ventriglia and colleagues did not find any significant differences in serum VEGF levels between the MDD patients and healthy controls [Dome et al 2008;Ventriglia et al 2009]. In a recent animal study, Elfving and colleagues reported that VEGF levels were significantly decreased in the hippocampus and frontal cortex of a genetic depression rat model [Elfving et al 2010]; however, no such difference was observed in serum levels of VEGF.…”

Section: Discussionsupporting

confidence: 88%

“…Recent evidence indicates that VEGF can act as a neuroprotective factor in the adult brain, inhibiting apoptosis and inducing growth of the associated vascular-neuronal networks. VEGF influences synaptic plasticity in hippocampus-dependent processes, such as learning and memory, and modulates synaptic transmission [Ventriglia et al 2009]. Exposure to unpredictable stress decreases the expression of VEGF in the hippocampus [Heine et al 2005].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

Kotan¹,

Sarandöl²,

Kırhan³

et al. 2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Abstract:Objective: Brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and leptin have been hypothesized to be involved in the neurobiology of depression. The aim of this study was to investigate BDNF, VEGF and leptin levels in patients with severe melancholic depression. Methods: A total of 40 drug-free patients with major depressive disorder (MDD) with melancholic features and 40 healthy controls were included in the study. Demographic information, psychiatric evaluation and physical examination were documented for both groups. Serum BDNF, VEGF levels were determined by enzyme-linked immunosorbent assay and leptin with radioimmunoassay methods. The Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale were applied to the patients. Results: There were no significant differences in serum BDNF, VEGF and leptin levels between the patient and control groups. There was a negative correlation between BDNF levels and the number of depressive episodes. It was noted that VEGF levels decreased with increasing severity of depression. Conclusions: These findings suggest that BDNF levels might be associated with the recurrence of depression and VEGF levels might be a determinant of the severity of depression.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

Kotan¹,

Sarandöl²,

Kırhan³

et al. 2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…In the same class of antidepressants, escitalopram did not alter VEGF plasma levels in depressed patients after 12 weeks of treatment [129]. It has to be mentioned that this latter study was conducted in a very small sample (25 subjects) without control of the co-morbidities, cardiovascular diseases or confounding factors, making conclusions very hard to make [129].…”

Section: Vascular Endothelial Growth Factor (Vegf)mentioning

confidence: 89%

“…An eight-week treatment with paroxetine appeared to decrease VEGF mRNA levels in peripheral leukocytes of depressed patients in positive correlation with clinical improvement [125]. In the same class of antidepressants, escitalopram did not alter VEGF plasma levels in depressed patients after 12 weeks of treatment [129]. It has to be mentioned that this latter study was conducted in a very small sample (25 subjects) without control of the co-morbidities, cardiovascular diseases or confounding factors, making conclusions very hard to make [129].…”

Section: Vascular Endothelial Growth Factor (Vegf)mentioning

confidence: 92%

“…However, data in human are more inconsistent [124]. In fact, while some authors observed higher serum or plasma VEGF concentrations in drug-free depressed patients [125][126][127] and in patients with acute episodes of MDD or bipolar disorders [128], others reported no significant difference compared to healthy controls [129]. It has been suggested that an elevation of VEGF expression may be a repair response to the neural damage that underlies the pathogenesis of depression [130].…”

Section: Vascular Endothelial Growth Factor (Vegf)mentioning

confidence: 99%

See 1 more Smart Citation

Neuroadaptations of the 5-HT System Induced by Antidepressant Treatments: Old and New Strategies

Haddjeri¹

2014

AAD

View full text Add to dashboard Cite

Major Depressive Disorder (MDD) is a common illness worldwide with severe socioeconomic consequences. Several hypotheses have been formulated to explain the physiopathology of depression as well as the mechanism of action of antidepressants but two of them had attracted much attention. The dominant monoaminergic hypothesis of depression links the physiopathology of MDD to a deficiency on cerebral serotonin (5-HT) and/or Norepinephrine (NE) levels; however, the relatively new neurogenic and neurotrophic hypothesis raises the possibility of an impaired neuroplasticity and/or depletion of neurotrophic factors in specific networks resulting on their structural deformity and functional impairment. An enormous body of evidence reported particular neuroadaptations following chronic administration of antidepressant drugs. In this review, we describe major adaptive changes in pre-and post-synaptic 5-HT neurotransmission as well as alterations in gene transcription and neurotrophic factors in response to long-term treatment with conventional antidepressants, new putative ones or novel promising drug candidates, all acting via 5-HT system.

show abstract

Electroconvulsive therapy increases temporarily plasma vascular endothelial growth factor in patients with major depressive disorder

et al. 2021

View full text Add to dashboard Cite

show abstract

VEGF serum levels in depressed patients during SSRI antidepressant treatment

Cited by 64 publications

References 33 publications

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

Neuroadaptations of the 5-HT System Induced by Antidepressant Treatments: Old and New Strategies

Electroconvulsive therapy increases temporarily plasma vascular endothelial growth factor in patients with major depressive disorder

Contact Info

Product

Resources

About